ImmuneDx has been evaluated in several research studies.
One study was a 4 month long blinded, placebo controlled, and randomized outcome study in 61 subjects. Compared to placebo, the use of ImmuneDx at 3 capsules per day, 20 days per month, resulted in statistically significant benefits in these important areas of assessment as follows:
- There was a significant reduction (P<0.01) in the incidence and frequency of respiratory immune challenges;
- There was a significant reduction (P<0.01) in the severity of respiratory immune challenges in the ImmuneDx group compared to placebo;
- There was a statistical trend (P<0.07) toward reduction in the duration of immune challenges in the ImmuneDx group.
Three additional studies were also undertaken to look at specific immune parameters. These three studies demonstrated the following:
- The proliferation of white blood cells (B and T-cells) was significantly increased (P<0.001) in the ImmuneDx group compared to placebo.
- The generation of antibodies showed a significant increase (P<0.001) in the ImmuneDx group compared to placebo.
- The phagocytic activity level of macrophages was significantly increased.
Plantiva controls all aspects of its product supply chain, which starts with knowing our growers, lab testing every step of the way, starting with the unprocessed plant materials and continuing through the multiple stages of processing to the finished extract materials.
Plantiva does not buy its ingredients from brokers and herb markets. We have spent over 15 years comparatively evaluating growing areas, standardizing extraction processing, and developing analytical methods for the plants used in making Plantiva products.
Our quality assurance team is managed by leading industry experts and includes other dedicated and experienced technicians around the world.
